Antman
et al., Management of Patients With STEMI: Executive Summary
J Am Coll Cardiol 2004;44:671-719
ACC/AHA
Guidelines for the Management of Patients With ST-Elevation Myocardial
Infarction—Executive Summary
A
Report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Writing Committee to Revise the
1999 Guidelines for the Management of Patients With Acute Myocardial
Infarction)
Developed
in Collaboration With the Canadian Cardiovascular Society
References
1. Mehta RH, Montoye CK, Gallogly M, et al., for
the GAP Steering Committee of the American College of Cardiology.
Improving quality of care for acute myocardial infarction: The Guidelines
Applied in Practice (GAP) Initiative. JAMA 2002;287:1269–76.
2. Jencks SF, Huff ED, Cuerdon T. Change in the
quality of care delivered to medicare beneficiaries, 1998–1999
to 2000–2001. JAMA 2003;289: 305–12.
3. Schneider EC, Zaslavsky AM, Epstein AM. Racial
disparities in the quality of care for enrollees in medicare managed
care. JAMA 2002; 287:1288–94.
4. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal
trends in the treatment of over 1.5 million patients with myocardial
infarction in the US from 1990 through 1999: the National Registry
of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000;36:2056–63.
5. American Heart Association. Heart Disease and
Stroke Statistics—2004 Update. Dallas, TX: American Heart
Association, 2003.
5a.
Wiviott SD, Morrow DA, Giugliano RP, et al. Performance of the thrombolysis
in myocardial infarction risk index for early acute coronary syndrome
in the National Registry of Myocardial Infarction: a simple risk
index predicts mortality in both ST and non-ST elevation myocardial
infarction. J Am Coll Cardiol 2003;41:365A–6A.
6. Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults. Executive Summary of the Third
Report of the National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
7. Levey AS, Coresh J, Balk E, et al. National Kidney
Foundation practice guidelines for chronic kidney disease: evaluation,
classification, and stratification. Ann Intern Med 2003;139:137–47.
8. National, Heart, Lung, and Blood Institute. Act
in Time to Heart Attack. Available at: http://:www.nhlbi.nih.gov/actintime,
2003. Accessed May 15, 2003.
9. American College of Cardiology. Guidelines Applied
in Practice. Available at: http://www.acc.org/gap/gap.htm.
Accessed May 15, 2003.
10. American Heart Association. Get With the Guidelines.
Available at http://www.americanheart.org/presenter.jhtml?identifier=1165.
Accessed May 15, 2003.
11. Topol EJ, Kereiakes DJ. Regionalization of
care for acute ischemic heart disease: a call for specialized centers.
Circulation 2003;107:1463–6.
12. Califf RM, Faxon DP. Need for centers to care
for patients with acute coronary syndromes. Circulation 2003;107:1467–70.
13. Willerson JT. Editor’s commentary:
centers of excellence. Circulation 2003;107:1471–2.
14. National Cholesterol Education Program. Third
Report of the Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment Panel III).
NIH publication No. 02–5125. Bethesda, Md: National Heart,
Lung, and Blood Institute, 2002. Guidelines, Related Tools, and
Patient Information. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm.
Accessed April 12, 2003.
15. Dracup K, Alonzo AA, Atkins JM, et al. The
physician’s role in minimizing prehospital delay in patients
at high risk for acute myocardial infarction: recommendations from
the National Heart Attack Alert Program. Working Group on Educational
Strategies to Prevent Prehospital Delay in Patients at High Risk
for Acute Myocardial Infarction. Ann Intern Med 1997;126:645–51.
16. Hedges JR, Feldman HA, Bittner V, et
al., for the REACT Study Group. Impact of community intervention
to reduce patient delay time on use of reperfusion therapy for acute
myocardial infarction: Rapid Early Action for Coronary Treatment
(REACT) trial. Acad Emerg Med 2000;7:862–72.
17. Canto JG, Zalenski RJ, Ornato JP, et al., for
the National Registry of Myocardial Infarction 2 Investigators.
Use of emergency medical services in acute myocardial infarction
and subsequent quality of care: observations from the National Registry
of Myocardial Infarction 2. Circulation 2002;106:3018–23.
18. Goldberg R, Goff D, Cooper L, et al. Age and
sex differences in presentation of symptoms among patients with
acute coronary disease: the Trial: Rapid Early Action for Coronary
Treatment (REACT). Coron Artery Dis 2000;11:399–407.
19. Hutchings CB, Mann NC, Daya M, et al., for
the Rapid Early Action for Coronary Treatment Study. Patients with
chest pain calling 9-1-1 or self-transporting to reach definitive
care: which mode is quicker? Am Heart J 2004;147:35–41.
20. Faxon D, Lenfant C. Timing is everything: motivating
patients to call 9–1–1 at onset of acute myocardial
infarction. Circulation 2001;104:1210–1.
21. U.S. Department of Health and Human Services,
Public Health Service, National Institutes of Health, National Heart,
Lung, and Blood Institute. NIH publication No. 01–3313. September
2001. Available at: http://www.nhlbi.nih.gov/health/prof/heart/mi/provider.pdf.
Accessed December 16, 2002.
22. Eisenberg MJ, Topol EJ. Prehospital administration
of aspirin in patients with unstable angina and acute myocardial
infarction. Arch Intern Med 1996;156:1506–10.
23. Fibrinolytic Therapy Trialists’ (FTT)
Collaborative Group. Indications for fibrinolytic therapy in suspected
acute myocardial infarction: collaborative overview of early mortality
and major morbidity results from all randomised trials of more than
1000 patients. Lancet 1994;343:311–22.
24. Gruppo Italiano per lo Studio della Streptochinasi
nell’Infarto Miocardico (GISSI). Effectiveness of intravenous
thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397–402.
25.
Armstrong PW, Collen D, Antman E. Fibrinolysis for acute myocardial
infarction: the future is here and now. Circulation 2003;107:2533–7.
26. The American Heart Association in collaboration
with the International Liaison Committee on Resuscitation. Guidelines
2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular
Care: Part 7: the era of reperfusion: section 1: acute coronary
syndromes (acute myocardial infarction). Circulation 2000;102 Suppl
I:I172–203.
27. Pedley DK, Bissett K, Connolly EM, et al. Prospective
observational cohort study of time saved by prehospital thrombolysis
for ST elevation myocardial infarction delivered by paramedics.
BMJ 2003;327:22–6.
28. Menown IB, Mackenzie G, Adgey AA. Optimizing
the initial 12-lead electrocardiographic diagnosis of acute myocardial
infarction. Eur Heart J 2000;21:275–83.
29. Case definitions for acute coronary heart disease
in epidemiology and clinical research studies: a statement from
the AHA Council on Epidemiology and Prevention; AHA Statistics Committee;
World Heart Federation Council on Epidemiology and Prevention; the
European Society of Cardiology Working Group on Epidemiology and
Prevention; Centers for Disease Control and Prevention; and the
National Heart, Lung, and Blood Institute. Circulation 2003;108:2543–9.
30. Come PC, Pitt B. Nitroglycerin-induced severe
hypotension and bradycardia in patients with acute myocardial infarction.
Circulation 1976;54: 624–8.
31. Antithrombotic Trialists’ Collaboration.
Collaborative meta-analysis of randomised trials of antiplatelet
therapy for prevention of death, myocardial infarction, and stroke
in high risk patients. BMJ 2002;324:71–86.
32. Sagar KA, Smyth MR. A comparative bioavailability
study of different aspirin formulations using on-line multidimensional
chromatography. J Pharm Biomed Anal 1999;21:383–92.
33. De Luca G, Suryapranata H, Zijlstra F, et al.,
for the ZWOLLE Myocardial Infarction Study Group. Symptom-onset-to-balloon
time and mortality in patients with acute myocardial infarction
treated by primary angioplasty. J Am Coll Cardiol 2003;42:991–7.
34. Boersma E, Mercado N, Poldermans D,
et al. Acute myocardial infarction. Lancet 2003;361:847–58.
35. De Luca G, Suryapranata H, Ottervanger JP,
et al. Time delay to treatment and mortality in primary angioplasty
for acute myocardial infarction: every minute of delay counts. Circulation
2004;109:1223–5.
36. Boersma E, Maas AC, Deckers JW, et al. Early
thrombolytic treatment in acute myocardial infarction: reappraisal
of the golden hour. Lancet 1996;348:771–5.
37. Zeymer U, Tebbe U, Essen R, et al., for the
ALKK-Study Group. Influence of time to treatment on early infarct-related
artery patency after different thrombolytic regimens. Am Heart J
1999;137:34–8.
38. Weaver WD, Cerqueira M, Hallstrom AP, et al.
Prehospital-initiated vs hospital-initiated thrombolytic therapy:
the Myocardial Infarction Triage and Intervention Trial. JAMA 1993;270:1211–6.
39. Brodie BR, Stuckey TD, Wall TC, et al. Importance
of time to reperfusion for 30-day and late survival and recovery
of left ventricular function after primary angioplasty for acute
myocardial infarction. J Am Coll Cardiol 1998;32:1312–9.
40. Brodie BR, Stuckey TD, Wall TC, et al. Importance
of time to reperfusion on outcomes with primary coronary angioplasty
for acute myocardial infarction (results from the Stent Primary
Angioplasty in Myocardial Infarction Trial). Am J Cardiol 2001;88:1085–90.
41. Williams DO. Treatment delayed is treatment
denied. Circulation 2004; 109:1806-8.
42. The Task Force on the Management of Acute Myocardial
Infarction of the European Society of Cardiology. Management of
acute myocardial infarction in patients presenting with ST-segment
elevation. Eur Heart J 2003;24:28–66.
43. Morrow DA, Antman EM, Charlesworth A, et al.
TIMI risk score for ST-elevation myocardial infarction: a convenient,
bedside, clinical score for risk assessment at presentation: an
intravenous nPA for treatment of infarcting myocardium early II
trial substudy. Circulation 2000;102: 2031–7.
44. Lee KL, Woodlief LH, Topol EJ, et al., for
the GUSTO-I Investigators. Predictors of 30-day mortality in the
era of reperfusion for acute myocardial infarction: results from
an international trial of 41,021 patients. Circulation 1995;91:1659–68.
45. Morrow DA, Antman EM, Giugliano RP,
et al. A simple risk index for rapid initial triage of patients
with ST-elevation myocardial infarction: an InTIME II substudy.
Lancet 2001;358:1571–5.
46.
Krumholz HM, Chen J, Wang Y, et al. Comparing AMI mortality among
hospitals in patients 65 years of age and older: evaluating methods
of risk adjustment. Circulation 1999;99:2986–92.
47. Granger CB, Goldberg RJ, Dabbous O, et al.,
for the Global Registry of Acute Coronary Events Investigators.
Predictors of hospital mortality in the Global Registry of Acute
Coronary Events. Arch Intern Med 2003; 163:2345–53.
48. Magid DJ, Calonge BN, Rumsfeld JS, et al.,
for the National Registry of Myocardial Infarction 2 and 3 Investigators.
Relation between hospital primary angioplasty volume and mortality
for patients with acute MI treated with primary angioplasty vs thrombolytic
therapy. JAMA 2000; 284:3131–8.
49. Nallamothu BK, Bates ER. Percutaneous coronary
intervention versus fibrinolytic therapy in acute myocardial infarction:
is timing (almost) everything? Am J Cardiol 2003;92:824–6.
50. Bonnefoy E, Lapostolle F, Leizorovicz A, et
al., for the Comparison of Angioplasty and Prehospital Thrombolysis
in Acute Myocardial Infarction study group. Primary angioplasty
versus prehospital fibrinolysis in acute myocardial infarction:
a randomised study. Lancet 2002; 360:825–9.
51. Steg PG, Bonnefoy E, Chabaud S, et al. Impact
of time to treatment on mortality after prehospital fibrinolysis
or primary angioplasty: data from the CAPTIM randomized clinical
trial. Circulation 2003;108:2851–6.
52. Widimsky P, Budesinsky T, Vorac D, et al. Long
distance transport for primary angioplasty vs immediate thrombolysis
in acute myocardial infarction: final results of the randomized
national multicentre trial: PRAGUE-2. Eur Heart J 2003;24:94–104.
53. Deleted in press.
54. Antman EM. General hospital management. In:
Julian DG, Braunwald E, eds. Management of Acute Myocardial Infarction.
London, England: WB Saunders, 1994;42–4.
54a. Lincoff AM, Califf RM, Van de Werf F, et
al., for the Global Use of Strategies To Open Coronary Arteries
(GUSTO) Investigators. Mortality at 1 year with combination platelet
glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy
vs conventional fibrinolytic therapy for acute myocardial infarction:
GUSTO V randomized trial. JAMA 2002;288:2130-5.
55. Zijlstra F, Beukema WP, van’t Hof AW,
et al. Randomized comparison of primary coronary angioplasty with
thrombolytic therapy in low risk patients with acute myocardial
infarction. J Am Coll Cardiol 1997;29:908–12.
56. Ribeiro EE, Silva LA, Carneiro R, et al. Randomized
trial of direct coronary angioplasty versus intravenous streptokinase
in acute myocardial infarction. J Am Coll Cardiol 1993;22:376–80.
57. Grinfield L, Berrocal D, Bellardi J, et al.
Fibrinolytics versus primary angioplasty in acute myocardial infarction
(FAP): a randomized trial in a community hospital in Argentina (abstr).
J Am Coll Cardiol 1996; 27:A222.
58. Zijlstra F, de Boer MJ, Hoorntje JC, et al.
A comparison of immediate coronary angioplasty with intravenous
streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680–4.
59. Widimsky P, Groch L, Zelízko M, et al.
Multicentre randomized trial comparing transport to primary angioplasty
vs immediate thrombolysis vs combined strategy for patients with
acute myocardial infarction presenting to a community hospital without
a catheterization laboratory: the PRAGUE study. Eur Heart J 2000;21:823–31.
60. de Boer MJ, Ottervanger JP, van’t Hof
AW, et al., for the Zwolle Myocardial Infarction Study Group. Reperfusion
therapy in elderly patients with acute myocardial infarction: a
randomized comparison of primary angioplasty and thrombolytic therapy.
J Am Coll Cardiol 2002; 39:1723–8.
61. Akhras F, Ousa AA, Swann G, et al. Primary
coronary angioplasty or intravenous thrombolysis for patients with
acute myocardial infarction?
Acute and late follow-up results in a new cardiac unit (abstr).
J Am Coll Cardiol 1997;29:A235–6.
62. Deleted in press.
63. Grines CL, Browne KF, Marco J, et al., for
the Primary Angioplasty in Myocardial Infarction Study Group. A
comparison of immediate angioplasty with thrombolytic therapy for
acute myocardial infarction. N Engl J Med 1993;328:673–9.
64. Gibbons RJ, Holmes DR, Reeder GS, et al, for
the Mayo Coronary Care Unit and Catheterization Laboratory Groups.
Immediate angioplasty compared with the administration of a thrombolytic
agent followed by conservative treatment for myocardial infarction.
N Engl J Med 1993; 328:685–91.
65.
Ribichini F, Steffenino G, Dellavalle A, et al. Comparison of thrombolytic
therapy and primary coronary angioplasty with liberal stenting for
inferior myocardial infarction with precordial ST-segment depression:
immediate and long-term results of a randomized study. J Am Coll
Cardiol 1998;32:1687–94.
66. García E, Elízaga J, Pérez-Castellano
N, et al. Primary angioplasty versus systemic thrombolysis in anterior
myocardial infarction. J Am Coll Cardiol 1999;33:605–11.
67. The Global Use of Strategies to Open Occluded
Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty
Substudy Investigators. A clinical trial comparing primary coronary
angioplasty with tissue plasminogen activator for acute myocardial
infarction. N Engl J Med 1997;336:1621–8.
68. Le May MR, Labinaz M, Davies RF, et al. Stenting
versus thrombolysis in acute myocardial infarction trial (STAT).
J Am Coll Cardiol 2001; 37:985–91.
69. Schömig A, Kastrati A, Dirschinger J,
et al., for the Stent versus Thrombolysis for Occluded Coronary
Arteries in Patients with Acute Myocardial Infarction Study Investigators.
Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared
with tissue plasminogen activator in acute myocardial infarction.
N Engl J Med 2000;343: 385–91.
70. Vermeer F, Oude Ophuis AJ, vd Berg EJ, et al.
Prospective randomised comparison between thrombolysis, rescue PTCA,
and primary PTCA in patients with extensive myocardial infarction
admitted to a hospital without PTCA facilities: a safety and feasibility
study. Heart 1999;82: 426–31.
71. Kastrati A, Mehilli J, Dirschinger J, et al.,
for the Stent versus Thrombolysis for Occluded Coronary Arteries
in Patients with Acute Myocardial Infarction (STOPAMI-2) Study.
Myocardial salvage after coronary stenting plus abciximab versus
fibrinolysis plus abciximab in patients with acute myocardial infarction:
a randomised trial. Lancet 2002;359:920–5.
72. Andersen HR, Nielsen TT, Rasmussen K, et al.,
for the DANAMI-2 Investigators. Thrombolytic therapy vs primary
percutaneous coronary intervention for myocardial infarction in
patients presenting to hospitals without on-site cardiac surgery:
a randomized controlled trial. JAMA 2002;287:1943–51.
73. Kastrati A, Mehilli J, Dirschinger J, et al.,
for the Stent versus Thrombolysis for Occluded Coronary Arteries
in Patients With Acute Myocardial Infarction (STOPAMI-2) Study.
A randomized trial of transfer for primary angioplasty versus on-site
thrombolysis in patients with high-risk myocardial infarction: the
Air Primary Angioplasty in Myocardial Infarction study. J Am Coll
Cardiol 2002;39:1713–9.
74. Andersen HR, Nielsen TT, Rasmussen K, et al.,
for the DANAMI-2 Investigators. A comparison of coronary angioplasty
with fibrinolytic therapy in acute myocardial infarction. N Engl
J Med 2003;349:733–42.
75. Hochman JS, Sleeper LA, Webb JG, et al., for
the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic
Shock (SHOCK) Investigators. Early revascularization in acute myocardial
infarction complicated by cardiogenic shock. N Engl J Med 1999;341:625–34.
76. Keeley EC, Boura JA, Grines CL. Primary angioplasty
versus intravenous thrombolytic therapy for acute myocardial infarction:
a quantitative review of 23 randomised trials. Lancet 2003;361:13–20.
76a. Melandri G. The obsession with primary angioplasty. Circulation
2003; 108:e1620.
77. Rogers WJ, Dean LS, Moore PB, et al., for the
Alabama Registry of Myocardial Ischemia Investigators. Comparison
of primary angioplasty versus thrombolytic therapy for acute myocardial
infarction. Am J Cardiol 1994;74:111–8.
78. Every NR, Parsons LS, Hlatky M, et al., for
the Myocardial Infarction Triage and Intervention Investigators.
A comparison of thrombolytic therapy with primary coronary angioplasty
for acute myocardial infarction. N Engl J Med 1996;335:1253–60.
79. Tiefenbrunn AJ, Chandra NC, French WJ, et al.
Clinical experience with primary percutaneous transluminal coronary
angioplasty compared with alteplase (recombinant tissue-type plasminogen
activator) in patients with acute myocardial infarction: a report
from the Second National Registry of Myocardial Infarction (NRMI-2).
J Am Coll Cardiol 1998; 31:1240–5.
80. Danchin N, Vaur L, Genès N, et al. Treatment
of acute myocardial infarction by primary coronary angioplasty or
intravenous thrombolysis in the “real world”: one-year
results from a nationwide French survey. Circulation 1999;99:2639–44.
81.
Berger PB, Ellis SG, Holmes DR, et al. Relationship between delay
in performing direct coronary angioplasty and early clinical outcome
in patients with acute myocardial infarction: results from the Global
Use of Strategies To Open Occluded Arteries in Acute Coronary Syndromes
(GUSTO-IIb) trial. Circulation 1999;100:14–20.
82. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship
of symptom onset-to-balloon time and door-to-balloon time with mortality
in patients undergoing angioplasty for acute myocardial infarction.
JAMA 2000; 283:2941–7.
83. Brodie BR, Stuckey TD, Hansen C, et al. Benefit
of coronary reperfusion before intervention on outcomes after primary
angioplasty for acute myocardial infarction. Am J Cardiol 2000;85:13–8.
84. Stone GW, Cox D, Garcia E, et al. Normal flow
(TIMI-3) before mechanical reperfusion therapy is an independent
determinant of survival in acute myocardial infarction: analysis
from the primary angioplasty in myocardial infarction trials. Circulation
2001;104:636–41.
85. Clements IP, Christian TF, Higano ST, et al.
Residual flow to the infarct zone as a determinant of infarct size
after direct angioplasty. Circulation 1993;88:1527–33.
86. Juliard JM, Feldman LJ, Golmard JL, et al.
Relation of mortality of primary angioplasty during acute myocardial
infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI)
time. Am J Cardiol 2003;91:1401–5.
87. Cragg DR, Friedman HZ, Bonema JD, et al. Outcome
of patients with acute myocardial infarction who are ineligible
for thrombolytic therapy. Ann Intern Med 1991;115:173–7.
88. Brodie BR, Weintraub RA, Stuckey TD, et al.
Outcomes of direct coronary angioplasty for acute myocardial infarction
in candidates and non-candidates for thrombolytic therapy. Am J
Cardiol 1991;67:7–12.
89. Himbert D, Juliard JM, Steg PG, et al. Primary
coronary angioplasty for acute myocardial infarction with contraindication
to thrombolysis. Am J Cardiol 1993;71:377–81.
90. Zahn R, Schuster S, Schiele R, et al., for
the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA)
Study Group. Comparison of primary angioplasty with conservative
therapy in patients with acute myocardial infarction and contraindications
for thrombolytic therapy. Cathet Cardiovasc Interv 1999;46:127–33.
91. Grzybowski M, Clements EA, Parsons L, et al.
Mortality benefit of immediate revascularization of acute ST-segment
elevation myocardial infarction in patients with contraindications
to thrombolytic therapy: a propensity analysis. JAMA 2003;290:1891–8.
92. Lotfi M, Mackie K, Dzavik V, et al.
Impact of delays to cardiac surgery after failed angioplasty and
stenting. J Am Coll Cardiol 2004;43: 337–42.
93. Dehmer GJ, Gantt DS. Coronary intervention
at hospitals without on-site cardiac surgery: are we pushing the
envelope too far? J Am Coll Cardiol 2004;43:343–5.
94. Antoniucci D, Santoro GM, Bolognese L, et al.
A clinical trial comparing primary stenting of the infarct-related
artery with optimal primary angioplasty for acute myocardial infarction:
results from the Florence Randomized Elective Stenting in Acute
Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol 1998;31:1234–9.
95. Rodríguez A, Bernardi V, Fernández
M, et al. In-hospital and late results of coronary stents versus
conventional balloon angioplasty in acute myocardial infarction:
Gianturco-Roubin in Acute Myocardial Infarction (GRAMI trial). Am
J Cardiol 1998;81:1286–91.
96. Suryapranata H, Ottervanger JP, Nibbering E,
et al. Long term outcome and cost-effectiveness of stenting versus
balloon angioplasty for acute myocardial infarction. Heart 2001;85:667–71.
97. Saito S, Hosokawa G, Tanaka S, et al., for
the PASTA Trial Investigators. Primary stent implantation is superior
to balloon angioplasty in acute myocardial infarction: final results
of the primary angioplasty versus stent implantation in acute myocardial
infarction (PASTA) trial. Cathet Cardiovasc Interv 1999;48:262–8.
98. Grines CL, Cox DA, Stone GW, et al., for the
Stent Primary Angioplasty in Myocardial Infarction Study Group.
Coronary angioplasty with or without stent implantation for acute
myocardial infarction. N Engl J Med 1999;341:1949–56.
99. Kawashima A, Ueda K, Nishida Y, et al. Quantitative
angiographic analysis of restenosis of primary stenting using Wiktor
stent for acute myocardial infarction: results from a multicenter
randomized PRISAM study (abstr). Circulation 1999;100 Suppl I:I856.
100. Maillard L, Hamon M, Khalife K, et al., for
the STENTIM-2 Investigators. A comparison of systematic stenting
and conventional balloon angioplasty during primary percutaneous
transluminal coronary angio-plasty
for acute myocardial infarction. J Am Coll Cardiol 2000;35: 1729–36.
101. Scheller B, Hennen B, Severin-Kneib S, et
al. Long-term follow-up of a randomized study of primary stenting
versus angioplasty in acute myocardial infarction. Am J Med 2001;110:1–6.
102. Zhu MM, Feit A, Chadow H, et al. Primary
stent implantation compared with primary balloon angioplasty for
acute myocardial infarction: a metaanalysis of randomized clinical
trials. Am J Cardiol 2001;88:297–301.
103. Stone GW, Grines CL, Cox DA, et al., for
the Controlled Abciximab and Device Investigation to Lower Late
Angioplasty Complications (CADILLAC) Investigators. Comparison of
angioplasty with stenting, with or without abciximab, in acute myocardial
infarction. N Engl J Med 2002;346:957–66.
104. Lemos PA, Saia F, Hofma SH, et al. Short-
and long-term clinical benefit of sirolimus-eluting stents compared
to conventional bare stents for patients with acute myocardial infarction.
J Am Coll Cardiol 2004; 43:704–8.
104a. Ellis SG, Armstrong P, Betriu A, et al.
Facilitated percutaneous coronary intervention versus primary percutaneous
coronary intervention: design and rationale of the Facilitated Intervention
with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
Am Heart J 2004; 147:E16.
105. The TIMI Research Group. Immediate vs delayed
catheterization and angioplasty following thrombolytic therapy for
acute myocardial infarction: TIMI II A results. JAMA 1988;260:2849–58.
106. Topol EJ, Califf RM, George BS, et al. A
randomized trial of immediate versus delayed elective angioplasty
after intravenous tissue plasminogen activator in acute myocardial
infarction. N Engl J Med 1987;317:581–8.
107. Sadanandan S, Buller C, Menon V, et al. The
late open artery hypothesis: a decade later. Am Heart J 2001;142:411–21.
108. Hochman JS, Sleeper LA, White HD, et al.,
for the SHOCK Investigators: Should We Emergently Revascularize
Occluded Coronaries for Cardiogenic Shock: one-year survival following
early revascularization for cardiogenic shock. JAMA 2001;285:190–2.
109. Dzavik V, Sleeper LA, Cocke TP, et al., for
the SHOCK Investigators. Early revascularization is associated with
improved survival in elderly patients with acute myocardial infarction
complicated by cardiogenic shock: a report from the SHOCK Trial
Registry. Eur Heart J 2003;24:828–37.
110. Dauerman HL, Goldberg RJ, Malinski M, et
al. Outcomes and early revascularization for patients greater than
or equal to 65 years of age with cardiogenic shock. Am J Cardiol
2001;87:844–8.
111. Dauerman HL, Ryan TJ, Piper WD, et al. Outcomes
of percutaneous coronary intervention among elderly patients in
cardiogenic shock: a multicenter, decade-long experience. J Invasive
Cardiol 2003;15:380–4.
112. Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis
with tissue plasminogen activator in acute myocardial infarction:
no additional benefit from immediate percutaneous coronary angioplasty.
Lancet 1988;1:197–203.
113. Ross AM, Coyne KS, Reiner JS, et al., for
the PACT (Plasminogenactivator Angioplasty Compatibility Trial)
Investigators: A randomized trial comparing primary angioplasty
with a strategy of short-acting thrombolysis and immediate planned
rescue angioplasty in acute myocardial infarction: the PACT trial.
J Am Coll Cardiol 1999;34:1954–62.
114. Montalescot G, Barragan P, Wittenberg O,
et al., for the ADMIRAL (Abciximab before Direct Angioplasty and
Stenting in Myocardial Infarction Regarding Acute and Long-Term
Follow-up). Investigators. Platelet glycoprotein IIb/IIIa inhibition
with coronary stenting for acute myocardial infarction. N Engl J
Med 2001;344:1895–903.
115. Zeymer U, Uebis R, Vogt A, et al., for the
ALKK-Study Group. Randomized comparison of percutaneous transluminal
coronary angioplasty and medical therapy in stable survivors of
acute myocardial infarction with single-vessel disease: a study
of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte.
Circulation 2003;108:1324–8.
116. Scheller B, Hennen B, Hammer B, et al., for
the SIAM III Study Group. Beneficial effects of immediate stenting
after thrombolysis in acute myocardial infarction. J Am Coll Cardiol
2003;42:634–41.
117. Braunwald E, Antman E, Beasley J, et al.
ACC/AHA 2002 guideline update for the management of patients with
unstable angina and non–STsegment elevation myocardial infarction:
summary article: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Committee on
the Management of Patients With Unstable Angina). J Am Coll Cardiol
2002;40:1366.
118. Stenestrand U, Wallentin L. Early revascularisation
and 1-year survival in 14-day survivors of acute myocardial infarction:
a prospective cohort study. Lancet 2002;359:1805–11.
119.
Alter DA, Tu JV, Austin PC, et al. Waiting times, revascularization
modality, and outcomes after acute myocardial infarction at hospitals
with and without on-site revascularization facilities in Canada.
J Am Coll Cardiol 2003;42:410–9.
120. Gupta M, Chang WC, Van de Werf F, et al.,
for the ASSENT II Investigators. International differences in in-hospital
revascularization and outcomes following acute myocardial infarction:
a multilevel analysis of patients in ASSENT-2. Eur Heart J 2003;24:1640–50.
121. Gibson CM, Karha J, Murphy SA, et al., for
the TIMI Study Group. Early and long-term clinical outcomes associated
with reinfarction following fibrinolytic administration in the thrombolysis
in myocardial infarction trials. J Am Coll Cardiol 2003;42:7–16.
122. Lablanche JM, Gueret P, Blanchard D, et al.
Beneficial effects of very early PTCA in patients with intravenous
thrombolysis for acute myocardial infarction: data from a nation-wide
registry in France (abstr). Circulation 2002;106 Suppl II:II630.
123. Fernandez-Aviles F, Alonso JJ, Castro-Beiras
A, et al. Prospective randomized trial comparing a routine invasive
strategy within 24 hours to thrombolysis versus an ischemia-guided
conservative approach to acute myocardial infarction with ST-segment
elevation: the Gracia-1 trial. Lancet 2004. In press.
124. ISIS-2 (Second International Study of Infarct
Survival) Collaborative Group. Randomised trial of intravenous streptokinase,
oral aspirin, both, or neither among 17,187 cases of suspected acute
myocardial infarction: ISIS-2. Lancet 1988;2:349–60.
125. Granger CB, Hirsch J, Califf RM, et al. Activated
partial thromboplastin time and outcome after thrombolytic therapy
for acute myocardial infarction: results from the GUSTO-I trial.
Circulation 1996;93:870–8.
126. White HD, Yusuf S. Issues regarding the use
of heparin following streptokinase therapy. J Thromb Thrombolysis
1995;2:5–10.
127. Thrombin-specific anticoagulation with bivalirudin
versus heparin in patients receiving fibrinolytic therapy for acute
myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358:1855–63.
128. Bertrand ME, Rupprecht HJ, Urban P, et al.
Double-blind study of the safety of clopidogrel with and without
a loading dose in combination with aspirin compared with ticlopidine
in combination with aspirin after coronary stenting: the Clopidogrel
Aspirin Stent International Cooperative Study (CLASSICS). Circulation
2000;102:624–9.
129. Mehta SR, Yusuf S, Peters RJ, et al., for
the Clopidogrel in Unstable angina to prevent Recurrent Events trial
(CURE) Investigators. Effects of pretreatment with clopidogrel and
aspirin followed by long-term therapy in patients undergoing percutaneous
coronary intervention: the PCI-CURE study. Lancet 2001;358:527–33.
130. Steinhubl SR, Berger PB, Mann JT III, et
al., for the CREDO (Clopidogrel for the Reduction of Events During
Observation) Investigators. Early and sustained dual oral antiplatelet
therapy following percutaneous coronary intervention: a randomized
controlled trial. JAMA 2002; 288:2411–20.
131. CYPHER™ sirolimus-eluting coronary
stent on RAPTORTM overthe-wire delivery system and CYPHER™
sirolimus-eluting coronary stent on RAPTORRAIL rapid exchange delivery
system [instructions for use]. Miami, FL: Cordis, a Johnson &
Johnson Company, April 2003.
132. TAXUS: paclitaxel-eluting coronary stent
system Monorail and over the wire coronary stent delivery system
[directions for use]. Natick, MA: Boston Scientific, March 2004.
133. Patrono C, Bachmann F, Baigent C, et al.
Expert consensus document on the use of antiplatelet agents: The
Task Force on the Use of Antiplatelet Agents in Patients With Atherosclerotic
Cardiovascular Disease of the European Society of Cardiology. Eur
Heart J 2004;25: 166–81.
134. Levine GN, Kern MJ, Berger PB, et al., for
the American Heart Association Diagnostic and Interventional Catheterization
Committee and Council on Clinical Cardiology. Management of patients
undergoing percutaneous coronary revascularization. Ann Intern Med
2003;139:123–36.
135. Lee DP, Herity NA, Hiatt BL, et al., for
the TIrofiban Given in the Emergency Room before Primary Angioplasty.
Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with
tirofiban before primary angioplasty improves angiographic outcomes:
results of the TIrofiban Given in the Emergency Room before Primary
Angioplasty (TIGER-PA) pilot trial. Circulation 2003;107:1497–501.
136. Finney SJ, Zekveld C, Elia A, et al. Glucose
control and mortality in critically ill patients. JAMA 2003;290:2041–7.
136a. Clement S, Braithwaite SS, Magee MF, et
al. Management of diabetes and hyperglycemia in hospitals. Diabetes
Care 2004;27:553–97.
137.
Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) final report.
Circulation 2002;106:3143–421.
138. Malan SS. Psychosocial adjustment following
MI: current views and nursing implications. J Cardiovasc Nurs 1992;6:57–70.
139. Havik OE, Maeland JG. Patterns of emotional
reactions after a myocardial infarction. J Psychosom Res 1990;34:271–85.
140. Moser DK, Dracup K. Is anxiety early after
myocardial infarction associated with subsequent ischemic and arrhythmic
events? Psychosom Med 1996;58:395–401.
141. Frasure-Smith N, Lespérance F, Talajic
M. The impact of negative emotions on prognosis following myocardial
infarction: is it more than depression? Health Psychol 1995;14:388–98.
142. Chae Cu, Hennekens CH. Beta blockers. In:
Hennekens CH, ed. Clinical Trials in Cardiovascular Disease: A Companion
to Braunwald’s Heart Disease. Philadelphia, PA: WB Saunders,
1999;79–94.
143. Latini R, Maggioni AP, Flather M, et al.
ACE inhibitor use in patients with myocardial infarction: summary
of evidence from clinical trials. Circulation 1995;92:3132–7.
144. ACE Inhibitor Myocardial Infarction Collaborative
Group. Indications for ACE inhibitors in the early treatment of
acute myocardial infarction: systematic overview of individual data
from 100,000 patients in randomized trials. Circulation 1998;97:2202–12.
145. Flather MD, Yusuf S, Køber L, et al.,
for the ACE-Inhibitor Myocardial Infarction Collaborative Group.
Long-term ACE-inhibitor therapy in patients with heart failure or
left-ventricular dysfunction: a systematic overview of data from
individual patients. Lancet 2000;355:1575– 81.
146. Pitt B, Zannad F, Remme WJ, et al., for the
Randomized Aldactone Evaluation Study Investigators. The effect
of spironolactone on morbidity and mortality in patients with severe
heart failure. N Engl J Med 1999;341:709–17.
147. Pitt B, Remme W, Zannad F, et al., for the
Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy
and Survival Study Investigators. Eplerenone, a selective aldosterone
blocker, in patients with left ventricular dysfunction after myocardial
infarction. N Engl J Med. 2003;348:1309–21.
148. Dickstein K, Kjekshus J, for the OPTIMAAL
Steering Committee of the Optimal Trial in Myocardial Infarction
with Angiotensin II Antagonist Losartan (OPTIMAAL) Study Group.
Effects of losartan and captopril on mortality and morbidity in
high-risk patients after acute myocardial infarction: the OPTIMAAL
randomised trial: Optimal Trial in Myocardial Infarction with Angiotensin
II Antagonist Losartan. Lancet 2002;360:752–60.
149. Pfeffer MA, McMurray JJ, Velazquez EJ, et
al., for the Valsartan in Acute Myocardial Infarction Trial Investigators.
Valsartan, captopril, or both in myocardial infarction complicated
by heart failure, left ventricular dysfunction, or both. N Engl
J Med 2003;349:1893–906.
150. Mann DL, Deswal A. Angiotensin-receptor blockade
in acute myocardial infarction: a matter of dose. N Engl J Med 2003;349:1963–5.
151. Gibbons RJ, Miller TD, Christian TF. Infarct
size measured by single photon emission computed tomographic imaging
with (99m) Tcsestamibi: a measure of the efficacy of therapy in
acute myocardial infarction. Circulation 2000;101:101–8.
152. Klocke FJ, Baird MG, Bateman TM, et al. ACC/AHA/ASNC
guidelines for the clinical use of cardiac radionuclide imaging:
a report of the American College of Cardiology/ American Heart Association
Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise
the 1995 Guidelines for the Clinical Use of Radionuclide Imaging).
Available at: http://www.acc.org/clinical/guidelines/radio/rni_fulltext.pdf,
2003. Accessed January 15, 2004.
153. Cheitlin MD, Armstrong WF, Aurigemma GP,
et al. ACC/AHA/ASE 2003 guideline update for the clinical application
of echocardiography: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE
Committee to Update the 1997 Guidelines for the Clinical Application
of Echocardiography). Available at: www.acc.org/clinical/guidelines/echo/index.pdf,
2003. Accessed January 15, 2004.
154. Mahrholdt H, Wagner A, Holly TA, et al. Reproducibility
of chronic infarct size measurement by contrast-enhanced magnetic
resonance imaging. Circulation 2002;106:2322–7.
155. Menon V, Slater JN, White HD, et
al. Acute myocardial infarction complicated by systemic hypoperfusion
without hypotension: report of the SHOCK trial registry. Am J Med
2000;108:374–80.
156.
Hochman JS, Boland J, Sleeper LA, et al., for the SHOCK Registry
Investigators. Current spectrum of cardiogenic shock and effect
of early revascularization on mortality: results of an International
Registry. Circulation 1995;91:873–81.
157. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA
guidelines for the evaluation and management of chronic heart failure
in the adult: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Committee to
Revise the 1995 Guidelines for the Evaluation and Management of
Heart Failure). Available at: http://www.acc.org/clinical/guidelines/failure/hf_index.htm,
2001. Accessed June 5, 2004.
158. Kinch JW, Ryan TJ. Right ventricular infarction.
N Engl J Med 1994; 330:1211–7.
159. Núñez L, de la Llana R, López
Sendón J, et al. Diagnosis and treatment of subacute free
wall ventricular rupture after infarction. Ann Thorac Surg 1983;35:525–9.
160. Guidelines for cardiopulmonary resuscitation
and emergency cardiac care: Emergency Cardiac Care Committee and
Subcommittees, American Heart Association: Part III: adult advanced
cardiac life support. JAMA 1992;268:2199–241.
161. Campbell RWF. Arrhythmias. In: Julian DG.
Braunwald E, eds. Management of Acute Myocardial Infarction. London,
England: WB Saunders, 1994;223–40.
162. Kontoyannis DA, Anastasiou-Nana MI, Kontoyannis
SA, et al. Intravenous amiodarone decreases the duration of atrial
fibrillation associated with acute myocardial infarction. Cardiovasc
Drugs Ther 2001;15: 155–60.
163. Ryan TJ, Antman EM, Brooks NH, et al. ACC/AHA
guidelines for the management of patients with acute myocardial
infarction: 1999 guideline update: a report of the American College
of Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee on Management of Acute Myocardial Infarction).
J Am Coll Cardiol 1999;34:890–911.
164. Gregoratos G, Abrams J, Epstein AE, et al.
ACC/AHA/NASPE 2002 guideline update for implantation of cardiac
pacemakers and antiarrhythmia devices: summary article: a report
of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update
the 1998 Pacemaker Guidelines). J Am Coll Cardiol 2002;40:1703–19.
165. Lamas GA, Ellenbogen KA. Evidence base for
pacemaker mode selection: from physiology to randomized trials.
Circulation 2004;109: 443–51.
166. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA
guidelines for coronary artery bypass graft surgery: a report of
the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee to Revise the 1991 Guidelines
for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American
Heart Association. J Am Coll Cardiol 1999;34: 1262–347.
167. Dyke C, Bhatia D. Inhibitors of the platelet
receptor glycoprotein IIb-IIIa and complications during percutaneous
coronary revascularization: management strategies for the cardiac
surgeon. J Cardiovasc Surg (Torino). 1999;40:505–16.
168. Yusuf S, Zhao F, Mehta SR, et al., for the
Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial
Investigators. Effects of clopidogrel in addition to aspirin in
patients with acute coronary syndromes without ST-segment elevation.
N Engl J Med 2001;345: 494–502.
169. Physician’s Desk Reference. Clopidogrel
package insert. Montvale, NJ: Medical Economics Co; 2756.
170. Gibbons RJ, Balady GJ, Bricker JT, et al.
ACC/AHA 2002 guideline update for exercise testing: a report of
the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee on Exercise Testing). Available
at: http://www.acc.org/clinical/guidelines/exercise/exercise_clean.pdf,
2002. Accessed February 12, 2004.
171. Théroux P, Waters DD, Halphen C, et
al. Prognostic value of exercise testing soon after myocardial infarction.
N Engl J Med 1979;301: 341–5.
172. DeBusk RF, Kraemer HC, Nash E, et al. Stepwise
risk stratification soon after acute myocardial infarction. Am J
Cardiol 1983;52:1161–6.
173. Krone RJ, Gillespie JA, Weld FM, et al. Low-level
exercise testing after myocardial infarction: usefulness in enhancing
clinical risk stratification. Circulation 1985;71:80–9.
174.
Valentine PA, Frew JL, Mashford ML, et al. Lidocaine in the prevention
of sudden death in the pre-hospital phase of acute infarction: a
double-blind study. N Engl J Med 1974;291:1327–31.
175. Ross J, Gilpin EA, Madsen EB, et al. A decision
scheme for coronary angiography after acute myocardial infarction.
Circulation 1989;79: 292–303.
176. Risk stratification and survival after myocardial
infarction. N Engl J Med 1983;309:331–6.
177. Zaret BL, Wackers TH, Terrin M, et al. Does
left ventricular ejection fraction following thrombolytic therapy
have the same prognostic impact described in the prethrombolytic
era? Results of the TIMI II Trial (abstr). J Am Coll Cardiol 1991;17:214A.
178. Roig E, Magriñá J, Garcia A,
et al. Prognostic value of exercise radionuclide angiography in
low-risk acute myocardial infarction survivors. Eur Heart J 1993;14:213–8.
179. Gibbons RJ, Abrams J, Chatterjee K, et al.
ACC/AHA 2002 guideline update for the management of patients with
chronic stable angina: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Committee to
Update the 1999 Guidelines for the Management of Patients with Chronic
Stable Angina). Available at: www.acc.org/clinical/guidelines/stable/stable.pdf
2002. Accessed March 18, 2004.
180. O’Neill WW. “Watchful waiting”
after thrombolysis: it’s time for a re-evaluation. J Am Coll
Cardiol 2003;42:17–9.
181. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC
scientific statement: AHA/ACC guidelines for preventing heart attack
and death in patients with atherosclerotic cardiovascular disease:
2001 update: a statement for healthcare professionals from the American
Heart Association and the American College of Cardiology. Circulation
2001;104: 1577–9.
182. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based
guidelines for cardiovascular disease prevention in women. Circulation
2004;109: 672–93.
183. Dalal H, Evans PH, Campbell JL. Recent developments
in secondary prevention and cardiac rehabilitation after acute myocardial
infarction. BMJ 2004;328:693–7.
184. Gutstein DE, Fuster V. Pathophysiologic bases
for adjunctive therapies in the treatment and secondary prevention
of acute myocardial infarction. Clin Cardiol 1998;21:
161–8.
185. CAPRIE Steering Committee. A randomised,
blinded, trial of clopidogrel versus aspirin in patients at risk
of ischaemic events (CAPRIE). Lancet 1996;348:1329–39.
186. Hurlen M, Smith P, Arnesen H. Effects of
warfarin, aspirin and the two combined, on mortality and thromboembolic
morbidity after myocardial infarction: the WARIS-II (Warfarin-Aspirin
Reinfarction Study) design. Scand Cardiovasc J 2000;34:168–71.
187. van Es RF, Jonker JJ, Verheugt FW, et al.,
for the Antithrombotics in the Secondary Prevention of Events in
Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin
after acute coronary syndromes (the ASPECT-2 study): a randomised
controlled trial. Lancet 2002;360:109–13.
188. Brouwer MA, van den Bergh PJ, Aengevaeren
WR, et al. Aspirin plus coumarin versus aspirin alone in the prevention
of reocclusion after fibrinolysis for acute myocardial infarction:
results of the Antithrombotics in the Prevention of Reocclusion
In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 2002;106:659–65.
189. Yusuf S, Sleight P, Pogue J, et al., for
the Heart Outcomes Prevention Evaluation Study Investigators. Effects
of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular
events in high-risk patients. N Engl J Med 2000;342:145–53.
190. Fox KM, for the EURopean trial On reduction
of cardiac events with Perindopril in stable coronary Artery disease
Investigators. Efficacy of perindopril in reduction of cardiovascular
events among patients with stable coronary artery disease: randomised,
double-blind, placebocontrolled, multicentre trial (the EUROPA study).
Lancet 2003;362:
782–8.
191.
Granger CB, McMurray JJ, Yusuf S, et al., for the CHARM Investigators
and Committees. Effects of candesartan in patients with chronic
heart failure and reduced left-ventricular systolic function intolerant
to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative
trial. Lancet 2003;362:772–6.
192. McMurray JJ, Ostergren J, Swedberg K, et
al., for the CHARM Investigators and Committees. Effects of candesartan
in patients with chronic heart failure and reduced left-ventricular
systolic function taking angiotensin-converting-enzyme inhibitors:
the CHARM-Added trial. Lancet 2003;362:767–71.
193. Yusuf S, Pfeffer MA, Swedberg K, et al.,
for the CHARM Investigators and Committees. Effects of candesartan
in patients with chronic heart failure and preserved left-ventricular
ejection fraction: the CHARMPreserved trial. Lancet 2003;362:777–81.
194. Executive Council of the Heart Failure Society
of America. Implications of recent clinical trials for heart failure
performance measures. J Card Fail 2004;10:4–5.
195. Deleted in press.
196. Antman E, Braunwald E. Acute myocardial infarction.
In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease: A Textbook
of Cardiovascular Medicine. 6th ed. Philadelphia, PA: WB Saunders,
2001: 1114–251. Chapter 5.
197. Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers
in chronic heart failure. Circulation 2003;107:1570–5.
198. Chen J, Radford MJ, Wang Y, et al. Are beta-blockers
effective in elderly patients who undergo coronary revascularization
after acute myocardial infarction? Arch Intern Med 2000;160:947–52.
199. Seventh report of the Joint National Committee
on the Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension
2003;41:1178 –9.
200. Hulley S, Grady D, Bush T, et al., for the
Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
Randomized trial of estrogen plus progestin for secondary prevention
of coronary heart disease in postmenopausal women. JAMA 1998;280:605–13.
201. Grady D, Herrington D, Bittner V, et al.,
for the HERS Research Group. Cardiovascular disease outcomes during
6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement
Study follow-up (HERS II). JAMA 2002;288:49–57.
202. Rossouw JE, Anderson GL, Prentice RL, et
al., for the Writing Group for the Women’s Health Initiative
Investigators. Risks and benefits of estrogen plus progestin in
healthy postmenopausal women: principal results from the Women’s
Health Initiative randomized controlled trial. JAMA 2002;288:321–33.
203. Cairns JA, Markham BA. Economics and efficacy
in choosing oral anticoagulants or aspirin after myocardial infarction.
JAMA 1995;273:965–7.
203a. Kris-Etherton PM, Lichtenstein AH, Howard
BV, Steinberg D, Witzman JL. Antioxidant vitamin supplements and
cardiovascular disease. Circulation. In press.
204. Glassman AH, O’Connor CM, Califf RM,
et al., for the Sertraline Antidepressant Heart Attack Randomized
Trial (SADHEART) Group. Sertraline treatment of major depression
in patients with acute MI or unstable angina. JAMA 2002;288:701–9.
205. Swenson JR, O’Connor CM, Barton D,
et al., for the Sertraline Antidepressant Heart Attack Randomized
Trial (SADHART) Group. Influence of depression and effect of treatment
with sertraline on quality of life after hospitalization for acute
coronary syndrome. Am J
Cardiol 2003;92:1271–6.
206. Berkman LF, Blumenthal J, Burg M, et al.,
for the Enhancing Recovery in Coronary Heart Disease Patients Investigators
(ENRICHD). Effects of treating depression and low perceived social
support on clinical events after myocardial infarction: the Enhancing
Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized
Trial. JAMA 2003;289: 3106–16.
207. Alonzo AA. Acute myocardial infarction and
posttraumatic stress disorder: the consequences of cumulative adversity.
J Cardiovasc Nurs 1999;13:33–45.3
|
